E2F3 loss has opposing effects on different pRB-deficient tumors, resulting in suppression of pituitary tumors but metastasis of medullary thyroid carcinomas
about
The SNF2-like helicase HELLS mediates E2F3-dependent transcription and cellular transformationHuman TFDP3, a novel DP protein, inhibits DNA binding and transactivation by E2FSkp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- miceRetinoblastoma family genesRB1: a prototype tumor suppressor and an enigmaThe role of Cdk5 in neuroendocrine thyroid cancerGenetic interaction between Rb and K-ras in the control of differentiation and tumor suppressionRb-mediated neuronal differentiation through cell-cycle-independent regulation of E2f3a.Context-dependent requirement for dE2F during oncogenic proliferationConstruction of a dual affinity tagged allele of the Rb1 tumor suppressor gene in the mouseSelective roles of E2Fs for ErbB2- and Myc-mediated mammary tumorigenesis.Tuberous sclerosis complex 1 regulates dE2F1 expression during development and cooperates with RBF1 to control proliferation and survival.E2F4 cooperates with pRB in the development of extra-embryonic tissues.HER2/Neu tumorigenesis and metastasis is regulated by E2F activator transcription factors.Inactivation of Rb and E2f8 synergizes to trigger stressed DNA replication during erythroid terminal differentiation.Tumor suppressor gene identification using retroviral insertional mutagenesis in Blm-deficient mice.Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification.Chromatin remodelers HELLS and UHRF1 mediate the epigenetic deregulation of genes that drive retinoblastoma tumor progression.Emerging roles of E2Fs in cancer: an exit from cell cycle controlSelective requirements for E2f3 in the development and tumorigenicity of Rb-deficient chimeric tissues.Novel retinoblastoma mutation abrogating the interaction to E2F2/3, but not E2F1, led to selective suppression of thyroid tumors.APC/C (Cdh1) controls the proteasome-mediated degradation of E2F3 during cell cycle exit.Concomitant inactivation of Rb and E2f8 in hematopoietic stem cells synergizes to induce severe anemiaModeling thyroid cancer in the mouse.E2F1 activation is responsible for pituitary adenomas induced by HMGA2 gene overexpressionGenetic alterations in thyroid cancer: the role of mouse models.Deletions of Retinoblastoma 1 (Rb1) and Its Repressing Target S Phase Kinase-associated protein 2 (Skp2) Are Synthetic Lethal in Mouse Embryogenesis.E2f3 in tumor macrophages promotes lung metastasis.Decreased expression of let-7c is associated with non-response of muscle-invasive bladder cancer patients to neoadjuvant chemotherapy.E2f3a and E2f3b contribute to the control of cell proliferation and mouse development.Upregulation of E2F8 promotes cell proliferation and tumorigenicity in breast cancer by modulating G1/S phase transition.Skp2 suppresses apoptosis in Rb1-deficient tumours by limiting E2F1 activity.Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality.Skin Tumors Rb(eing) Uncovered.Antitumor mechanisms when pRb and p53 are genetically inactivated.Thyroid C-Cell Biology and Oncogenic Transformation.MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status.Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics.Inhibition of pituitary tumors in Rb mutant chimeras through E2f4 loss reveals a key suppressive role for the pRB/E2F pathway in urothelium and ganglionic carcinogenesis.Rb-independent E2F3 promotes cell proliferation and alters expression of genes involved in metabolism and inflammation.
P2860
Q24299494-31BB74FA-9B73-4F01-B700-F4146DCEBB5CQ24309023-C681FC8B-AF47-41E2-86A5-C44ABF5A47B6Q24595114-EA6EB9CB-56BF-4CE7-9D7B-7D3D79E15856Q24683690-5763FEC0-711A-4B56-9287-50A6E18C73FDQ26866393-69F5CF9B-61A2-4016-8FB4-E804A7B10F3BQ28392185-DCA491DB-6E35-4072-AF53-066CE5B6BD8DQ28504596-B50CF7C5-0D66-4C64-A090-3C68DF645E8AQ33289781-E0380E76-9819-4808-A739-EF42ECB0C0E9Q33373668-FEC3D051-9580-468E-A585-6F895984A597Q33643357-D6FB5688-B242-40FC-B6EC-479AD9E8507FQ33657413-3D30D6C1-807E-4C70-B339-C609AB8418FBQ33680727-4F30D91B-F251-4630-A0B8-D96AD2E37E9EQ33704032-B4D9B4C0-93F8-4339-BE7D-F4D87CC89BE6Q33794153-FA8EF60C-3F99-4C4B-95A5-A984905B9A31Q34056434-B696F055-CAFB-4FB6-96BE-30C1653C7AA2Q34549869-6D2BC27B-D0F6-4A6D-AB03-448C4B1681B1Q34585359-D27E892B-D03C-44D4-B5B9-43D776544063Q34654497-F2046636-D355-47B2-9E9D-278824CF5B72Q35009182-EF5687E3-8ECF-4B54-974D-B97C4FF65817Q35676302-8DC7A579-4D33-4B3C-84C6-4549AF787C42Q35713250-B1887553-4EF6-495D-A5A5-3351BD48861DQ35984086-F58C0BBC-E6B3-4505-998E-BC478976CD89Q35995237-0B05C505-01A3-4692-9BDE-7060575602A0Q36297044-8813488C-D5CF-4645-8EFE-521852931D7FQ36567837-C851EF0B-5E69-436D-BD11-E212A5653F02Q36696228-BF34CB8F-0ECE-49AB-A5C7-796600AD8E47Q36876207-1AFF6649-6C88-42A6-A832-2E29F0F86A25Q36885525-6B339E84-602A-446F-90A2-5E4C3357EE8EQ37033304-CAA1BD1D-F32A-4E73-AEFB-6D19DBB7AD14Q37033617-D18DD440-0CAD-492B-A7C5-180428ED5F55Q37269121-CC22781A-0B73-4D25-828D-693090E3A311Q37695433-370ECB0B-B4D1-4B3B-8A8A-DD849A096F8DQ37761003-A24FF129-73AB-41E4-B3B2-F8645F8F1337Q38175052-7AD88659-2C31-4B75-8E7D-6C13A298CE64Q38285170-010CBDFC-D832-4CAF-A8AB-118C03587062Q38614485-48109AFE-0FCC-496B-9267-BD05466C8DCAQ39518813-AAC1BABD-7FB5-4ED9-AE54-243224E7AC99Q40549645-E9EB2975-9CC0-4C2D-989C-46A76F0688A3Q41810752-9B4BA5FD-1C98-470A-8EBC-9E055409CAF2Q41983684-023344E6-185B-47C1-8222-F1EF1CB2C9A9
P2860
E2F3 loss has opposing effects on different pRB-deficient tumors, resulting in suppression of pituitary tumors but metastasis of medullary thyroid carcinomas
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
E2F3 loss has opposing effects ...... f medullary thyroid carcinomas
@ast
E2F3 loss has opposing effects ...... f medullary thyroid carcinomas
@en
type
label
E2F3 loss has opposing effects ...... f medullary thyroid carcinomas
@ast
E2F3 loss has opposing effects ...... f medullary thyroid carcinomas
@en
prefLabel
E2F3 loss has opposing effects ...... f medullary thyroid carcinomas
@ast
E2F3 loss has opposing effects ...... f medullary thyroid carcinomas
@en
P2093
P2860
P1476
E2F3 loss has opposing effects ...... f medullary thyroid carcinomas
@en
P2093
Eunice Y Lee
Jacqueline A Lees
Roderick T Bronson
Ulrike Ziebold
P2860
P304
P356
10.1128/MCB.23.18.6542-6552.2003
P407
P577
2003-09-01T00:00:00Z